On the occasion of the American Academy of Neurology Annual Meeting, we are pleased to share the promising results of the ME&MGopen™ study, which aims to better understand generalized myasthenia gravis through digital biomarkers.

These initial results reinforce the potential of our digital tool, ME&MG, to enhance patient engagement and real-world understanding of this rare disease.

 Check out our Press releases for all the details.